View : 332 Download: 0

Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer

Title
Impact of COPD Treatment on Survival in Patients with Advanced Non-Small Cell Lung Cancer
Authors
Jo H.Park S.Kim N.E.Park S.Y.Ryu Y.J.Chang J.H.Lee J.H.
Ewha Authors
장중현이진화류연주박소영박소정김남은조현지
SCOPUS Author ID
장중현scopus; 이진화scopusscopus; 류연주scopus; 박소영scopus; 박소정scopus; 김남은scopusscopus; 조현지scopus
Issue Date
2022
Journal Title
Journal of Clinical Medicine
ISSN
2077-0383JCR Link
Citation
Journal of Clinical Medicine vol. 11, no. 9
Keywords
bronchodilatorchronic obstructive pulmonary diseaseinhaled corticosteroidsnon-small cell lung cancersurvival
Publisher
MDPI
Indexed
SCIE; SCOPUS WOS scopus
Document Type
Article
Abstract
Chronic obstructive pulmonary disease (COPD) is associated with a poor prognosis in patients with non-small cell lung cancer (NSCLC). However, the impact of COPD treatment on the survival of patients with advanced NSCLC remains uncertain. We retrospectively investigated COPD patients among patients newly diagnosed with advanced NSCLC between September 2005 and August 2019 at a university hospital. The clinical characteristics, lung function, and survival outcomes were analyzed and compared between patients who did and did not receive COPD treatment. Among 221 patients with advanced NSCLC and COPD, 124 patients received treatment for COPD and 97 patients did not receive treatment for COPD. Forced expiratory volume in 1 s (FEV1 ) % predicted value was greater in the no-treatment group than in the COPD treatment group (p < 0.001). The median overall survival (OS) of the treatment group was 10.7 months, while that of the no-treatment group was 8.7 months (p = 0.007). In the multivariate analysis, COPD treatment was independently associated with improved OS (hazard ratio 0.71, 95% confidence interval 0.53–0.95, and p = 0.021). COPD treatment was associated with improved OS in patients with advanced NSCLC and COPD. Therefore, pretreatment spirometry and maximal treatment for COPD may offer a chance of optimal management for patients with advanced NSCLC. © 2022 by the authors. Licensee MDPI, Basel, Switzerland.
DOI
10.3390/jcm11092391
Appears in Collections:
의과대학 > 의학과 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE